APA (7th ed.) Citation

HS, R., M, C., C, Y., A, J. C., AM, W., C, I., . . . LJ, E. (2025). Pexidartinib and standard neoadjuvant therapy in the adaptively randomized I-SPY2 trial for early breast cancer. Breast cancer research and treatment, 209(3), 487. https://doi.org/10.1007/s10549-024-07555-9

Chicago Style (17th ed.) Citation

HS, Rugo, et al. "Pexidartinib and Standard Neoadjuvant Therapy in the Adaptively Randomized I-SPY2 Trial for Early Breast Cancer." Breast Cancer Research and Treatment 209, no. 3 (2025): 487. https://doi.org/10.1007/s10549-024-07555-9.

MLA (9th ed.) Citation

HS, Rugo, et al. "Pexidartinib and Standard Neoadjuvant Therapy in the Adaptively Randomized I-SPY2 Trial for Early Breast Cancer." Breast Cancer Research and Treatment, vol. 209, no. 3, 2025, p. 487, https://doi.org/10.1007/s10549-024-07555-9.